Abiraterone acetate fixed-dosed combinations with ibuprofen-based therapeutic eutectic and deep eutectic solvents
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
39875032
DOI
10.1016/j.ijpharm.2025.125279
PII: S0378-5173(25)00115-2
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer treatment(s), Deep eutectic solvent(s), Enabling formulation(s), Eutectic mixture(s), Novel pharmaceutic(s), Therapeutic deep eutectic solvent(s),
- MeSH
- abirateron * chemie aplikace a dávkování MeSH
- fixní kombinace léků MeSH
- ibuprofen * chemie aplikace a dávkování MeSH
- kapryláty chemie MeSH
- kyseliny dekanové chemie MeSH
- kyseliny laurové chemie MeSH
- protinádorové látky * chemie aplikace a dávkování MeSH
- rozpouštědla * chemie MeSH
- rozpustnost MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- abirateron * MeSH
- decanoic acid MeSH Prohlížeč
- fixní kombinace léků MeSH
- ibuprofen * MeSH
- kapryláty MeSH
- kyseliny dekanové MeSH
- kyseliny laurové MeSH
- lauric acid MeSH Prohlížeč
- octanoic acid MeSH Prohlížeč
- protinádorové látky * MeSH
- rozpouštědla * MeSH
In recent years, deep eutectic solvents (DESs) with their outstanding solubilization properties have emerged as strong candidates for oral enabling formulations of poorly soluble drugs. This study explores the use of drug-based therapeutic DESs (THEDESs) to solubilize a poorly soluble compound with the aim of providing a fixed-dose combination of two complementary therapeutic agents. Specifically, potential anticancer effects of ibuprofen (IBU) are harnessed in a novel type of THEDES to dissolve higher amounts of abiraterone acetate (AbAc), an antitumor agent. Four IBU-based combinations were studied: 1:4 M ratio with octanoic acid (OctA), 1:5 with nonanoic acid (NonA), 1:3 with decanoic acid (DeA) or 1:2 with dodecanoic acid (DoA). Fatty acids of different chain lengths were analyzed and discussed considering surface charge densities obtained via quantum chemistry. The THEDESs listed could apparently dissolve AbAc amounts up to 1311.0 ± 125.4 mg/g in IBU:OctA THEDES, 1151.7 ± 22.2 mg/g in IBU:NonA, 1160.4 ± 33.5 mg/g in IBU:DeA, and 231.3 ± 10.7 mg/g in IBU:DoA. In vitro dissolution of the simultaneously released drugs reached 37.8 ± 9.0 % to 64.2 ± 1.0 % for IBU and 5.0 ± 3.3 % to 19.4 ± 0.1 % for AbAc. This increased to between 60.4 ± 2.8 % and 79.4 ± 5.0 % of released IBU, and 23.6 ± 1.0 % to 57.3 ± 5.8 % of released AbAc, with 20 % (w/w) Tween 80 added to the formulations. This showed the significant potential of drug-containing THEDESs as solubilizing agents for poorly soluble drugs, in the form of fixed-dose combinations of synergistic APIs.
Citace poskytuje Crossref.org